What is OrganOx?
OrganOx is a medical technology company dedicated to enhancing organ preservation and transplantation outcomes through innovative organ perfusion systems. Emerging as a spin-out from a prominent academic institution, OrganOx aims to revolutionize organ care by developing technologies that extend the viability and usability of donor organs. The company's core mission is to improve clinical results and increase the success rate of transplants by redefining the standards of organ preservation outside the human body. Its focus on cutting-edge medical devices positions it within the rapidly evolving healthtech sector.
How much funding has OrganOx raised?
OrganOx has raised a total of $174.6M across 2 funding rounds:
Private Equity
$32.6M
Other Financing Round
$142M
Private Equity (2023): $32.6M with participation from Lauxera Capital Partners
Other Financing Round (2025): $142M led by Sofina, University Of Oxford Department Of Physics, Avidity Partners, Soleus Capital, HealthQuest Capital, Longwall Ventures, Lauxera Capital Partners, and BGF
Key Investors in OrganOx
Sofina
Sofina, a private equity and venture capital firm established in 1980, specializes in growth capital and various stages of investment, with a broad portfolio including digital transformation, healthcare, and financial services worldwide.
Avidity Partners
Avidity Partners, LLC provides post-confirmation Chapter 11 Trustee services, focusing on liquidation, asset sales, and corporate dissolutions, having distributed over two billion dollars to creditors.
Soleus Capital
Soleus Capital is a healthcare investment firm concentrating on innovative life sciences sectors such as biotech, medtech, diagnostics, and genomics, investing across the healthcare lifecycle to advance cutting-edge solutions.
What's next for OrganOx?
With the recent influx of major enterprise-level funding, OrganOx is poised for significant expansion and further technological development. The substantial capital infusion, particularly the recent 'Other Financing Round', suggests a strategic move towards scaling operations, advancing research and development, and potentially broadening its market reach. The company's focus on critical areas within healthcare, such as organ transplantation, indicates a strong potential for impact and growth. Future endeavors will likely involve further clinical validation, regulatory approvals, and the commercialization of its advanced organ perfusion systems, solidifying its role as a key innovator in the medical technology landscape.
See full OrganOx company page
